New FAERS Analysis Flags Musculoskeletal Safety Signals for Semaglutide, Liraglutide, and Tirzepatide

A new pharmacovigilance analysis published in Cureus on September 23, 2026 examines musculoskeletal adverse event signals for semaglutide, liraglutide, and tirzepatide in the US FDA Adverse Event Reporting System (FAERS), adding to a growing body of literature probing whether incretin therapies carry risks to muscle, joints, and connective tissue beyond their well-characterized gastrointestinal effects.

What Happened

The study mined FAERS, the FDA's spontaneous-reporting database, for musculoskeletal and connective-tissue disorder reports associated with the three incretin therapies. Disproportionality analyses of this kind compare how often an event appears with a suspect drug against a database baseline to flag potential safety signals. The paper lands amid an active research cycle: a separate FAERS study published in May 2026 in Naunyn-Schmiedeberg's Archives of Pharmacology analyzed roughly 15,000 de-duplicated musculoskeletal reports for incretin-based diabetes drugs and linked GLP-1 receptor agonists to signals including back pain and myalgia, and tirzepatide to muscle atrophy, with median onset for muscle-related events within roughly 30 days of starting therapy.

The new Cureus analysis focuses the same investigative lens on the three most-used incretin brands individually — semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound).

Who Is Affected

• Patients on long-term GLP-1 therapy — muscle-related complaints during weight loss are common in clinic discussions; spontaneous-report signals help prioritize what deserves controlled study.
• Prescribers — awareness of emerging musculoskeletal signal literature supports monitoring during the first months of therapy, when prior analyses suggest onset is concentrated.
• Researchers — FAERS signals are hypothesis-generating, not proof of causation; they define endpoints for the pharmacoepidemiology studies that follow.

Timeline

• May 2026 — A FAERS pharmacovigilance study of incretin-based diabetes drugs reports musculoskeletal signals for GLP-1 receptor agonists and tirzepatide, with early onset patterns.
• September 23, 2026 — The new Cureus analysis of semaglutide-, liraglutide-, and tirzepatide-associated musculoskeletal reports is published.

What This Means for Researchers

Rapid weight loss itself catabolizes lean mass, which complicates interpretation: a drug-associated signal for myalgia or muscle atrophy may reflect treatment effect, disease background, or reporting bias. FAERS cannot separate these — it has no denominator, suffers from reporting heterogeneity, and duplicates are common. What signals do is shape surveillance priorities.

For research-material quality specifically, pharmacovigilance literature is a reminder that adverse-event attribution assumes the administered product is what it claims to be. With compounded and research-grade incretin materials circulating widely, misattributed harm is a real confounder. Our pages on semaglutide and tirzepatide summarize the regulatory landscape around these compounds.

How to Verify Your Peptides

Whether you procure incretin materials for laboratory research or assess vendor claims, verification is the control that makes safety data interpretable:

• Demand a certificate of analysis from an independent third-party laboratory for every batch — our trusted third-party testing lab guide explains what a legitimate COA contains.
• Verify identity and purity by HPLC and mass spectrometry before use — the semaglutide purity testing workflow and tirzepatide HPLC testing guide cover standard methods.
• Reject lots with documentation gaps; adulterated product is a documented problem in this category.

Safe Alternatives

For researchers sourcing incretin compounds, our vendor directory lists suppliers evaluated on testing transparency and documentation practices.

Sources

Peer-reviewed pharmacovigilance literature; regulatory announcements.